Gyre Therapeutics, Inc., a biopharmaceutical entity tracking on NASDAQ, has seen notable insider activity alongside major strategic announcements regarding its operations and market positioning.
Specifically, Ye Weiguo, the Chief Operating Officer (COO) of Gyre Therapeutics, reported transactions involving the disposition of company common stock. Across two dates in May 2026, namely May 22 and May 26, Mr. Ye executed sales totaling $45,680.
The details of these sales indicate that a total of 7,500 shares of common stock were disposed of. The pricing for these transactions varied slightly, ranging from $6.08 to $6.1001 per share. On May 22, Mr. Ye sold an initial batch of 3,500 shares, followed by a subsequent transaction on May 26 involving the sale of 4,000 shares.
It is also noted that these selling activities occurred after Mr. Ye had acquired 7,500 shares of common stock through the exercise of existing stock options. These initial acquisitions were valued at $5,625 and were executed at a cost of $0.75 per share. The underlying stock options used for this purchase were fully vested and carried an expiration date set for October 31, 2030.
Following the reported sales transactions, Mr. Ye's direct holdings in Gyre Therapeutics, Inc. common stock amount to 700,000 shares.
Beyond the insider trading reports, recent developments highlight significant strategic advancements for Gyre Therapeutics. The company recently announced the completion of its acquisition of Cullgen Inc., a clinical-stage biopharmaceutical firm. This transaction was executed via an all-stock deal valued at approximately $300 million.
This corporate development also resulted in key leadership changes within the organization. Dr. Ying Luo, who previously served as CEO of Cullgen, has been appointed to take on the roles of President and CEO of Gyre Therapeutics. Furthermore, Dr. Luo will join the company's Board of Directors. The existing structure retains Ping Zhang as Chairman of the Board of Directors.
In parallel regulatory developments, the National Medical Products Administration (NMPA) in China accepted Gyre’s New Drug Application for F351. This drug is designed to treat chronic hepatitis B-induced liver fibrosis. This acceptance follows an earlier decision by the administration that granted priority review status for the F351 application.
The positive corporate and regulatory momentum was further underscored by external financial analysis. H.C. Wainwright reiterated a 'Buy' rating on Gyre Therapeutics, setting a price target of $18.00. This recommendation reflects positive sentiment following the announcement of the major acquisition.
Overall, these various reported transactions and announcements signal substantial strategic movements for Gyre Therapeutics across both its corporate structure and regulatory pathways within the biopharmaceutical sector.
Risks
- The stock is trading near its 52-week low of $5.87, and shares have declined by 42% over the past year, indicating market volatility.
- Insider selling activity by COO Ye Weiguo suggests potential profit-taking or liquidity needs amidst operational changes.
- While H.C. Wainwright maintains a 'Buy' rating with an $18.00 target, the stock's current trading level remains significantly below this projection.
More from Insider Trading
Risks
- The stock is trading near its 52-week low of $5.87, and shares have declined by 42% over the past year, indicating market volatility.
- Insider selling activity by COO Ye Weiguo suggests potential profit-taking or liquidity needs amidst operational changes.
- While H.C. Wainwright maintains a 'Buy' rating with an $18.00 target, the stock's current trading level remains significantly below this projection.